STOCK TITAN

[S-8 POS] Third Harmonic Bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Third Harmonic Bio, Inc. (THRD) has filed Post-Effective Amendment No. 1 to four previously effective Form S-8 registration statements (File Nos. 333-267445, 333-270935, 333-278232 and 333-286189). The amendments deregister all shares of common stock that remain unsold under the company’s 2019 Stock Incentive Plan, 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan.

The action follows the company’s wind-down: the board adopted a Plan of Dissolution on Apr 10 2025, shareholders approved it on Jun 5 2025, and a Certificate of Dissolution was filed on Jul 31 2025, becoming effective immediately. In line with the plan, THRD has terminated all securities offerings and is amending the S-8 filings to remove any unsold securities from registration. The amendment was signed by Chief Financial & Business Officer Christopher Murphy; no additional signatures are required under Rule 478.

Third Harmonic Bio, Inc. (THRD) ha presentato l'Emendamento Post-Efficace n. 1 a quattro dichiarazioni di registrazione Form S-8 precedentemente efficaci (Numeri di protocollo 333-267445, 333-270935, 333-278232 e 333-286189). Gli emendamenti cancellano la registrazione di tutte le azioni ordinarie ancora invendute nell'ambito del Piano di Incentivi Azionari 2019, del Piano di Incentivi Azionari 2022 e del Piano di Acquisto Azionario per Dipendenti 2022.

Questa azione segue la fase di chiusura dell'azienda: il consiglio ha adottato un Piano di Scioglimento il 10 aprile 2025, gli azionisti lo hanno approvato il 5 giugno 2025 e un Certificato di Scioglimento è stato depositato il 31 luglio 2025, diventando efficace immediatamente. In linea con il piano, THRD ha terminato tutte le offerte di titoli e sta modificando le registrazioni S-8 per rimuovere i titoli invenduti dalla registrazione. L'emendamento è stato firmato dal Chief Financial & Business Officer Christopher Murphy; non sono richieste ulteriori firme ai sensi della Regola 478.

Third Harmonic Bio, Inc. (THRD) ha presentado la Enmienda Post-Efectiva No. 1 a cuatro declaraciones de registro Form S-8 previamente vigentes (Números de archivo 333-267445, 333-270935, 333-278232 y 333-286189). Las enmiendas cancelan la inscripción de todas las acciones ordinarias que permanecen sin vender bajo el Plan de Incentivos de Acciones 2019, el Plan de Incentivos de Capital 2022 y el Plan de Compra de Acciones para Empleados 2022 de la compañía.

Esta acción sigue al proceso de liquidación de la empresa: la junta adoptó un Plan de Disolución el 10 de abril de 2025, los accionistas lo aprobaron el 5 de junio de 2025 y se presentó un Certificado de Disolución el 31 de julio de 2025, que entró en vigor de inmediato. En línea con el plan, THRD ha finalizado todas las ofertas de valores y está enmendando los registros S-8 para eliminar cualquier valor no vendido de la inscripción. La enmienda fue firmada por el Director Financiero y de Negocios Christopher Murphy; no se requieren firmas adicionales según la Regla 478.

Third Harmonic Bio, Inc. (THRD)는 이전에 효력이 있었던 네 건의 Form S-8 등록 명세서(파일 번호 333-267445, 333-270935, 333-278232 및 333-286189)에 대해 사후 효력 수정안 1호를 제출했습니다. 이 수정안은 회사의 2019년 주식 인센티브 플랜, 2022년 주식 인센티브 플랜 및 2022년 직원 주식 구매 플랜에 따라 판매되지 않은 모든 보통주 주식을 등록 말소합니다.

이 조치는 회사의 청산 절차에 따른 것으로, 이사회는 2025년 4월 10일 해산 계획을 채택했고, 주주들은 2025년 6월 5일 이를 승인했으며, 2025년 7월 31일 해산 증명서가 제출되어 즉시 효력이 발생했습니다. 계획에 따라 THRD는 모든 증권 공모를 종료했으며, S-8 등록 명세서를 수정하여 판매되지 않은 증권을 등록에서 제거하고 있습니다. 이 수정안은 최고재무 및 비즈니스 책임자 크리스토퍼 머피가 서명했으며, 규칙 478에 따라 추가 서명은 필요하지 않습니다.

Third Harmonic Bio, Inc. (THRD) a déposé l'Amendement Post-Efficace n° 1 à quatre déclarations d'enregistrement Form S-8 précédemment en vigueur (numéros de dossier 333-267445, 333-270935, 333-278232 et 333-286189). Les amendements radient toutes les actions ordinaires non vendues dans le cadre du Plan d'Incitation à l'Actionnariat 2019, du Plan d'Incitation au Capital 2022 et du Plan d'Achat d'Actions des Employés 2022 de la société.

Cette action fait suite à la liquidation de la société : le conseil d'administration a adopté un Plan de Dissolution le 10 avril 2025, les actionnaires l'ont approuvé le 5 juin 2025, et un Certificat de Dissolution a été déposé le 31 juillet 2025, prenant effet immédiatement. Conformément au plan, THRD a mis fin à toutes les offres de titres et modifie les dépôts S-8 pour retirer les titres non vendus de l'enregistrement. L'amendement a été signé par le Directeur Financier et Commercial Christopher Murphy ; aucune signature supplémentaire n'est requise selon la Règle 478.

Third Harmonic Bio, Inc. (THRD) hat die Post-Effective Amendment Nr. 1 zu vier zuvor wirksamen Form S-8-Registrierungserklärungen (Aktenzeichen 333-267445, 333-270935, 333-278232 und 333-286189) eingereicht. Die Änderungen streichen alle noch unverkauften Stammaktien aus der Registrierung im Rahmen des Aktienanreizplans 2019, des Aktienanreizplans 2022 und des Mitarbeiteraktienkaufplans 2022 des Unternehmens.

Diese Maßnahme folgt der Abwicklung des Unternehmens: Der Vorstand verabschiedete am 10. April 2025 einen Auflösungsplan, die Aktionäre genehmigten diesen am 5. Juni 2025, und am 31. Juli 2025 wurde eine Auflösungsurkunde eingereicht, die sofort wirksam wurde. Im Einklang mit dem Plan hat THRD alle Wertpapierangebote eingestellt und ändert die S-8-Anmeldungen, um nicht verkaufte Wertpapiere aus der Registrierung zu entfernen. Die Änderung wurde vom Chief Financial & Business Officer Christopher Murphy unterzeichnet; weitere Unterschriften sind gemäß Regel 478 nicht erforderlich.

Positive
  • None.
Negative
  • Deregistration of all remaining unissued shares confirms there will be no further equity opportunities for investors.
  • Certificate of Dissolution effective 31 Jul 2025 finalizes the company’s liquidation process.

Insights

TL;DR: THRD deregisters unsold S-8 shares after formal dissolution—mechanical step confirming company wind-down.

The filing is a housekeeping move that finalizes Third Harmonic Bio’s exit from the public markets. Once the certificate of dissolution became effective on 31 Jul 2025, the company was required to terminate outstanding registration statements and remove any securities that were never issued. Investors already knew of the liquidation plan (board approval 10 Apr 2025; shareholder approval 5 Jun 2025), so today’s amendment merely completes the regulatory checklist. While impactful in that it confirms no future equity issuance, the economic effect had been priced in when the dissolution was announced.

Third Harmonic Bio, Inc. (THRD) ha presentato l'Emendamento Post-Efficace n. 1 a quattro dichiarazioni di registrazione Form S-8 precedentemente efficaci (Numeri di protocollo 333-267445, 333-270935, 333-278232 e 333-286189). Gli emendamenti cancellano la registrazione di tutte le azioni ordinarie ancora invendute nell'ambito del Piano di Incentivi Azionari 2019, del Piano di Incentivi Azionari 2022 e del Piano di Acquisto Azionario per Dipendenti 2022.

Questa azione segue la fase di chiusura dell'azienda: il consiglio ha adottato un Piano di Scioglimento il 10 aprile 2025, gli azionisti lo hanno approvato il 5 giugno 2025 e un Certificato di Scioglimento è stato depositato il 31 luglio 2025, diventando efficace immediatamente. In linea con il piano, THRD ha terminato tutte le offerte di titoli e sta modificando le registrazioni S-8 per rimuovere i titoli invenduti dalla registrazione. L'emendamento è stato firmato dal Chief Financial & Business Officer Christopher Murphy; non sono richieste ulteriori firme ai sensi della Regola 478.

Third Harmonic Bio, Inc. (THRD) ha presentado la Enmienda Post-Efectiva No. 1 a cuatro declaraciones de registro Form S-8 previamente vigentes (Números de archivo 333-267445, 333-270935, 333-278232 y 333-286189). Las enmiendas cancelan la inscripción de todas las acciones ordinarias que permanecen sin vender bajo el Plan de Incentivos de Acciones 2019, el Plan de Incentivos de Capital 2022 y el Plan de Compra de Acciones para Empleados 2022 de la compañía.

Esta acción sigue al proceso de liquidación de la empresa: la junta adoptó un Plan de Disolución el 10 de abril de 2025, los accionistas lo aprobaron el 5 de junio de 2025 y se presentó un Certificado de Disolución el 31 de julio de 2025, que entró en vigor de inmediato. En línea con el plan, THRD ha finalizado todas las ofertas de valores y está enmendando los registros S-8 para eliminar cualquier valor no vendido de la inscripción. La enmienda fue firmada por el Director Financiero y de Negocios Christopher Murphy; no se requieren firmas adicionales según la Regla 478.

Third Harmonic Bio, Inc. (THRD)는 이전에 효력이 있었던 네 건의 Form S-8 등록 명세서(파일 번호 333-267445, 333-270935, 333-278232 및 333-286189)에 대해 사후 효력 수정안 1호를 제출했습니다. 이 수정안은 회사의 2019년 주식 인센티브 플랜, 2022년 주식 인센티브 플랜 및 2022년 직원 주식 구매 플랜에 따라 판매되지 않은 모든 보통주 주식을 등록 말소합니다.

이 조치는 회사의 청산 절차에 따른 것으로, 이사회는 2025년 4월 10일 해산 계획을 채택했고, 주주들은 2025년 6월 5일 이를 승인했으며, 2025년 7월 31일 해산 증명서가 제출되어 즉시 효력이 발생했습니다. 계획에 따라 THRD는 모든 증권 공모를 종료했으며, S-8 등록 명세서를 수정하여 판매되지 않은 증권을 등록에서 제거하고 있습니다. 이 수정안은 최고재무 및 비즈니스 책임자 크리스토퍼 머피가 서명했으며, 규칙 478에 따라 추가 서명은 필요하지 않습니다.

Third Harmonic Bio, Inc. (THRD) a déposé l'Amendement Post-Efficace n° 1 à quatre déclarations d'enregistrement Form S-8 précédemment en vigueur (numéros de dossier 333-267445, 333-270935, 333-278232 et 333-286189). Les amendements radient toutes les actions ordinaires non vendues dans le cadre du Plan d'Incitation à l'Actionnariat 2019, du Plan d'Incitation au Capital 2022 et du Plan d'Achat d'Actions des Employés 2022 de la société.

Cette action fait suite à la liquidation de la société : le conseil d'administration a adopté un Plan de Dissolution le 10 avril 2025, les actionnaires l'ont approuvé le 5 juin 2025, et un Certificat de Dissolution a été déposé le 31 juillet 2025, prenant effet immédiatement. Conformément au plan, THRD a mis fin à toutes les offres de titres et modifie les dépôts S-8 pour retirer les titres non vendus de l'enregistrement. L'amendement a été signé par le Directeur Financier et Commercial Christopher Murphy ; aucune signature supplémentaire n'est requise selon la Règle 478.

Third Harmonic Bio, Inc. (THRD) hat die Post-Effective Amendment Nr. 1 zu vier zuvor wirksamen Form S-8-Registrierungserklärungen (Aktenzeichen 333-267445, 333-270935, 333-278232 und 333-286189) eingereicht. Die Änderungen streichen alle noch unverkauften Stammaktien aus der Registrierung im Rahmen des Aktienanreizplans 2019, des Aktienanreizplans 2022 und des Mitarbeiteraktienkaufplans 2022 des Unternehmens.

Diese Maßnahme folgt der Abwicklung des Unternehmens: Der Vorstand verabschiedete am 10. April 2025 einen Auflösungsplan, die Aktionäre genehmigten diesen am 5. Juni 2025, und am 31. Juli 2025 wurde eine Auflösungsurkunde eingereicht, die sofort wirksam wurde. Im Einklang mit dem Plan hat THRD alle Wertpapierangebote eingestellt und ändert die S-8-Anmeldungen, um nicht verkaufte Wertpapiere aus der Registrierung zu entfernen. Die Änderung wurde vom Chief Financial & Business Officer Christopher Murphy unterzeichnet; weitere Unterschriften sind gemäß Regel 478 nicht erforderlich.

As filed with the Securities and Exchange Commission on July 31, 2025

Registration No. 333-  

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-267445

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270935

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-278232

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-286189

UNDER

THE SECURITIES ACT OF 1933

 

 

THIRD HARMONIC BIO, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   83-4553503
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification Number)

 

1700 Montgomery Street, Suite 210

San Francisco, California 94111

  94111
(Address of Principle Executive Offices)   (Zip Code)

2022 Equity Incentive Plan

2022 Employee Stock Purchase Plan

(Full title of the plans)

Natalie Holles

Chief Executive Officer

Third Harmonic Bio, Inc.

1700 Montgomery Street, Suite 210

San Francisco, California 94111

(Name and Address of Agent for Service)

(209) 727-2457

(Telephone Number, Including Area Code, of Agent for Service)

 

 

Please send copies of all communications to:

Effie Toshav, Esq.

Robert A. Freedman, Esq.

Ryan Mitteness, Esq.

Fenwick & West LLP

401 Union Street, 5th Floor

Seattle, WA 98101

(206) 389-4510

 

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act. ☐

 

 
 


DEREGISTRATION OF SECURITIES

These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (each, a “Registration Statement” and, collectively, the “Registration Statements”), previously filed by Third Harmonic Bio, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):

 

   

Registration Statement on Form S-8 (File No. 333-267445), originally filed with the SEC on September 15, 2022, pertaining to the registration of 2,536,953 shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), under the Company’s 2019 Stock Incentive Plan, as amended, 4,710,545 shares of Common Stock under the Company’s 2022 Equity Incentive Plan (the “2022 Plan”) and 369,079 shares of Common Stock under the Company’s 2022 Employee Stock Purchase Plan (the “2022 ESPP”).

 

   

Registration Statement on Form S-8 (File No. 333-270935), originally filed with the SEC on March 29, 2023, pertaining to the registration of an additional 2,208,253 shares of Common Stock under the 2022 Plan and an additional 403,422 shares of Common Stock under the 2022 ESPP.

 

   

Registration Statement on Form S-8 (File No. 333-278232), originally filed with the SEC on March 26, 2024, pertaining to the registration of an additional 2,032,440 shares of Common Stock under the 2022 Plan and an additional 406,488 shares of Common Stock under the 2022 ESPP.

 

   

Registration Statement on Form S-8 (File No. 333-286189), originally filed with the SEC on March 27, 2025, pertaining to the registration of an additional 2,254,514 shares of Common Stock under the 2022 Plan and an additional 450,902 shares of Common Stock under the 2022 ESPP.

On April 10, 2025, the Company’s board of directors approved a Plan of Dissolution (the “Plan of Dissolution”) which, following the approval by the Company’s stockholders at the annual meeting held on June 5, 2025, authorizes the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution. On July 31, 2025, the Company filed its Certificate of Dissolution with the Secretary of State of the State of Delaware, which became effective upon filing.

In connection with the Plan of Dissolution, the Company has terminated any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, California, on this 31th day of July, 2025.

 

THIRD HARMONIC BIO, INC.
By:   /s/ Christopher Murphy
  Christopher Murphy
  Chief Financial and Business Officer

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

FAQ

Why did Third Harmonic Bio (THRD) file Post-Effective Amendments to its Form S-8 registrations?

Because the company is liquidating under a shareholder-approved Plan of Dissolution and must remove any unsold securities from registration.

Which registration statements are affected by THRD's deregistration filing?

File Nos. 333-267445, 333-270935, 333-278232, and 333-286189 covering shares under the 2019 Plan, 2022 Equity Incentive Plan and 2022 ESPP.

When did THRD’s Certificate of Dissolution become effective?

July 31 2025, the same date these Post-Effective Amendments were filed.

When did shareholders approve THRD’s Plan of Dissolution?

At the annual meeting held on June 5 2025.

What happens to the unsold shares previously registered on Form S-8?

All unsold shares are now removed from registration and cannot be issued going forward.
Third Harmonic Bio Inc

NASDAQ:THRD

THRD Rankings

THRD Latest News

THRD Latest SEC Filings

THRD Stock Data

242.79M
35.24M
9.13%
100.66%
3.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO